This study will test the safety and tolerability (how the body reacts to the drug) of REGN668 and placebo (an inactive substance that contains no medicine) in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
4 IV Cohorts (Dose 1, 2, 3, \& 4)
Unnamed facility
Baltimore, Maryland, United States
The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.
Time frame: 85 days
Pharmacokinetics: Serum concentrations of REGN668 over time.
Time frame: 85 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.